Investors still hot for Valeant debt despite looser terms
Canadian drug maker Valeant Pharmaceuticals is hoping to complete a large debt refinancing which will extend maturities and loosen covenants, though leveraged loan investors are still likely to lap up the new debt, sources said.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: